SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
Ticker SymbolSIGA
Company nameSIGA Technologies Inc
IPO dateSep 09, 1997
CEODr. Diem Nguyen, Ph.D.
Number of employees46
Security typeOrdinary Share
Fiscal year-endSep 09
Address31 East 62Nd Street
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10065
Phone12126729100
Websitehttps://www.siga.com/
Ticker SymbolSIGA
IPO dateSep 09, 1997
CEODr. Diem Nguyen, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data